HGS Fires Round 2 At Genentech Over Lupus Drug IP

Law360, New York (April 13, 2011, 8:12 PM EDT) -- Human Genome Sciences on Tuesday continued its assault on Genentech Inc. and cancer center City of Hope, filing its second declaratory judgment suit this year over patents covering the lupus drug Benlysta.

HGS launched its latest attack against Genentech and City of Hope in the U.S. District Court for the District of Delaware, seeking a declaration that the patent-in-suit, U.S. Patent Number 7,923,221 — known as the Cabilly III patent — was invalid and not infringed by HGS' lupus drug Benlysta. The U.S. Food and Drug...
To view the full article, register now.